This channel includes news on cardiovascular care delivery, including how patients are diagnosed and treated, cardiac care guidelines, policies or legislation impacting patient care, device recalls that may impact patient care, and cardiology practice management.
The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.
For artificial intelligence to truly transform care, the healthcare industry must address certain challenges. Jens Eldrup-Jorgensen, MD, a veteran vascular surgeon and member of the Society for Vascular Surgery, explains in a guest editorial.
The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks.
Advanced practice providers have enjoyed a raise in total cash compensation of 16% over the last five years. That’s a sharper upward pay trajectory than physicians or nurses have seen over that period.
Johns Hopkins All Children’s Hospital in St. Petersburg, Fla., plans to file post-trial motions against the $261 million judgment that a Florida jury last week ordered the institution to pay.
The COVID-19 pandemic undid years and years of progress in terms of preventing CVD-related deaths. What can be done to help reverse this trend once and for all?
The new-look syringes are causing significant issues when used with syringe infusion pumps. This is a Class I recall, which means the FDA believes the products “may cause serious injuries or death.”
Less than a week after the famous Kowalski family won a $261 million civil judgment against a Johns Hopkins facility in Florida, Maya Kowalski is announcing she will slap the hospital with a criminal complaint alleging sexual assault.
The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.
The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks.
Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.
